Skip to main content

Table 2 Patient characteristics, glomerular filtration rate (GFR), renal acidosis, use of corticosteroids, hypertension and renal osteodystrophy by CKD stage

From: Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study

CKD stage

CKD stage I

CKD stage II

CKD stage III

CKD stage IV+V

Number of patients

44

11

13

13

% of total patients

54.3%

13.6%

16.0%

16.0%

Median GFR (IQR 25th-75th percentile)

141.3 (105.1-161.9)

71.3 (65.8-82.8)

43.5 (36.4-5.9)

15.3 (11.7-20.4)

Renal acidosis

Overall treated

11.4%

0.0%

30.8%

23.1%

Treated with bicarbonate (%)

2.3%

0.0%

23.1%

23.1%

Treated with potassium/sodium citrate (%)

9.1%

0.0%

7.7%

0.0%

Hypertension

Patients on any BP meds (%)

54.5%

72.7%

46.2%

76.9%

Patients on ACE-I or ARB (%)

43.2%

72.7%

53.8%

46.2%

Patients on non-ACE-I (diuretics, Ca-channel blocker etc.) (%)

18.2%

27.3%

15.4%

53.8%

Patients on multiple therapies (%)

22.7%

36.4%

15.4%

23.1%

Steroid therapy

% of patients on corticosteroid medications

18.2%

18.2%

7.7%

7.7%

% Renal osteodystrophy treated with

calcium containing phosphate binders

0.0%

9.1%

15.4%

46.2%

non-calcium containing phosphate binders

0.0%

0.0%

0.0%

15.4%

vitamin D analog

6.8%

9.1%

0.0%

46.2%

active vitamin D analog

0.0%

9.1%

30.8%

53.8%

Abnormally high PTH (N=1.6-6.9 pmol/L)

6.8%

36.4%

69.2%

84.6%

Abnormally high FGF-23 (N=10-50 pg/mL)

13.6%

27.3%

53.8%

92.3%

Abnormally high phosphate (N=0.80-1.33 mmol/L)

40.9%

45.5%

15.4%

84.6%

  1. IQR=Inter quartile range, %=percent, BP=blood pressure, PTH=parathyroid hormone, FGF-23=fibroblast growth factor 23, N=normal.